TABLE 3.
Regression-adjusted percentage change in BMD from baseline in each group, after matching.
| Group | △BMD%a |
|||||
| FN |
TH |
L1–4 |
||||
| Unadjusted | Adjustedc | Unadjusted | Adjustedc | Unadjusted | Adjustedc | |
| Total | ||||||
| Gr A | −2.52 (8.37) | −1.64 (1.19) | −0.27 (9.43) | 0.73 (0.70) | −1.45 (9.35) | 0.05 (2.05) |
| Gr B | −3.08 (9.04) | −2.45 (1.17) | −1.36 (9.61) | −1.82 (1.33) | −1.50 (9.44) | −0.96 (1.59) |
| p-valueb | 0.362 | <0.001 | 0.044 | <0.001 | 0.807 | <0.001 |
| AOT + | ||||||
| Gr A | −0.74 (10.66) | 1.14 (3.34) | 2.10 (10.04) | 3.17 (0.97) | 0.30 (10.33) | 1.08 (4.55) |
| Gr B | −2.21 (10.93) | −1.09 (3.28) | −2.43 (10.71) | −1.15 (0.98) | 0.85 (10.9) | 1.21 (4.05) |
| p-valueb | 0.121 | <0.001 | 0.009 | <0.001 | 0.970 | 0.494 |
| AOT– | ||||||
| Gr A | −3.64 (5.89) | −3.10 (0.87) | −2.22 (7.98) | −1.03 (1.27) | −2.27 (8.30) | −1.09 (1.17) |
| Gr B | −3.65 (7.98) | −3.38 (1.06) | −1.12 (10.45) | −2.05 (2.02) | −2.90 (8.72) | −2.53 (1.06) |
| p-valueb | 0.908 | 0.032 | 0.705 | 0.001 | 0.650 | <0.001 |
FN, femoral neck; L1–4, lumbar vertebrae 1–4; TH, total hip; BMD, bone mineral density; Gr, group; AOT, anti-osteoporotic therapy.
Data are presented as median (interquartile range).
+, presence; −, absence.
a△BMD%: [(BMD 3 years later - BMD at baseline)/BMD at baseline] × 100%.
bComparison of △BMD% among groups at each site.
cPredicted change in BMD was calculated by multiple regression analysis after adjusting disease duration, baseline DAS28-ESR, glucocorticoid, b/tsDMARDs therapy.